About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristant #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« IPO Webinar on Estoppel at the PTAB | Main | Conference & CLE Calendar »

May 24, 2015

Comments

Simplistic, but sexy too, which is why sensationalist outlets like IP360 picked it up uncritically. Thanks for for giving the matter more than PWC or its parrots.

Your observations simply do not fit the "desired" narrative.

I am reminded of the particular scene in a classic American movie in which a certain little canine pulls aside a curtain revealing a man pushing a lot of buttons and turning a lot of gears...

Thank you for supporting my own prior suspicions of this PwC report, which were expressed as follows:
It is hard to attribute such a relatively small new patent suits reduction to any one legal change as being the most important. I think it is the availability and wide use of IPRs [and some CBMs] to defendants if they are sued, whereas PwC thinks it is Alice-101 [which you have disproved]. Attorney fee sanctions and claim ambiguity challenges are not really up that much, per other studies. Presumably all of these new factors could contribute to some extent to patent suit reductions. I think their impact will increase in the future by reducing private venture capital funding of new suits by NPEs because they impact the PAE business model. The PAE business model depends on the approximately 97% of litigation defendants that "settle" to avoid high discovery and other litigation costs (obtained at low costs by PAEs) rather than on the few actual final litigation awards affirmed by the Fed. Cir.
[N.B. this is not about pharma patents.]

The comments to this entry are closed.

October 2019

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31